Pharmacogenomics and Post-Operative Nausea and Vomiting
| Status: | Recruiting |
|---|---|
| Conditions: | Hospital |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/12/2019 |
| Start Date: | May 2, 2018 |
| End Date: | October 2019 |
| Contact: | Shonie Buenvenida, RN |
| Email: | Buenvenida.Shonie@mayo.edu |
| Phone: | 1-866-265-9263 |
Using Pharmacogenomics (PGx) Results to Guide Post-operative Nausea and Vomiting (PONV) Treatment Practices: A Pilot Study
The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic
data to guide post-operative nausea and vomiting treatment in the bariatric surgical
population. The hypothesis is that using genotypic variation in CYP2D6 to select the
appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in
the bariatric surgical population.
data to guide post-operative nausea and vomiting treatment in the bariatric surgical
population. The hypothesis is that using genotypic variation in CYP2D6 to select the
appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in
the bariatric surgical population.
Inclusion Criteria
- A Mayo Clinic patient scheduled to undergo any bariatric surgical procedure, including
Roux-en-Y gastric bypass, sleeve gastrectomy, or duodenal switch.
- Patient age 18 or above.
- Patients must understand and provide written informed consent and HIPAA authorization
prior to initiation of any study-specific procedures.
- Patient is willing to engage in a medication adjustment as part of their clinical
visit (when needed).
Exclusion Criteria
- Patient with uncontrolled concurrent illness including psychiatric illness, or
situations that would limit compliance with the study requirements or the ability to
willingly give written informed consent.
- Patients that deny access to their medical records for research purposes will not be
included in this study. Also any patient who will be unable to have genetic testing at
minimum of 1 week prior to scheduled surgery or with allergies to ondansetron or
granisetron.
- Any patient with prior genetic testing that is readily available in the medical record
will be excluded from this study.
- Any patient that is pregnant
We found this trial at
1
site
200 First Street SW
Rochester, Minnesota 55905
Rochester, Minnesota 55905
507-284-2511
Principal Investigator: Yvette N Martin, MD, PhD
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
